NCT03919292: Neratinib + Valproate in Advanced Solid Tumors, w/Expansion Cohort in Ras-Mutated Ca

NCT03919292
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: RAS
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1|Phase 2
Drug Category: Tyrosine-Kinase Inhibitor, Misc Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Only patients with RAS-mutated solid tumors are elgibile for phase 2
Exclusions: Patients with rurrent or prior known meningeal metastases; Patients with symptomatic untreated brain metastases – see trial for details; Patients with previous therapy with neratinib
https://ClinicalTrials.gov/show/NCT03919292

Comments are closed.

Up ↑